Telitacicept IgA Nephropathy Trial Slows Kidney Decline, Vor Bio Says

Telitacicept IgA Nephropathy

Summary

Vor Bio said its experimental Telitaciceptl drug slowed kidney function loss in a late-stage study of IgA nephropathy patients. Over two years, the drug met the main goal and cut the risk of a confirmed 30% decline by 89%, and no treated patient reached a kidney failure endpoint, the company said.

Key Highlights

  • Telitacicept cut the risk of a confirmed 40% decline in kidney function by 81% versus placebo.
  • Five placebo patients reached a kidney failure endpoint, including two who needed dialysis.
  • Urine protein levels fell 60.3% from baseline after 104 weeks, against a 0.9% rise on placebo.
  • All figures come from the company, which announced them on Thursday.

What Happened?
US biotech Vor Bio (VOR.O) said on Thursday that its Telitacicept IgA nephropathy trial met its main goal. IgA nephropathy is a disease that can eventually lead to kidney failure. According to the company, patients on the drug largely kept their kidney function over two years, while those on placebo declined more steeply. Vor Bio also said the drop in urine protein held after patients moved from weekly to every-other-week dosing.

Why is it Important?

Kidney failure is the outcome doctors most want to prevent in IgA nephropathy, and the company reported that no patient on Telitacicept reached the predefined kidney failure endpoint. Five patients on placebo did, and two of them needed dialysis. Protein in the urine is a key marker in this disease, and it fell by more than 60% on the drug.

Impact and Implications

The results strengthen the case for a drug that is already approved in one market. Telitacicept received conditional approval in China in June for adults with IgA nephropathy at risk of disease progression. Vor Bio holds rights to develop and market it outside Greater China, so the new data matter most to the company’s plans in other regions. The report doesn’t say whether the findings will be published or peer-reviewed, and it gives no safety data.

What Happens Next?

The report does not say whether Vor Bio plans to apply to regulators outside China or when it might. What is known is that the company holds those rights and now has two-year data to point to. Anyone tracking the TelitaciceptIgA nephropathy programme should watch for a fuller data release and any regulatory filing.

Search